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ABSTRACT
Glioma stem cell (GSC)-targeted therapy is expected to be one of the most 
innovative approaches to treat patients with glioblastoma (GBM). A number of the 
drugs that restrain the signaling pathway essential for GSC maintenance have been 
under clinical trials. Here, we identified fluspirilene, a traditional antipsychotic drug, 
as a GSC-targeting agent, selected from thousands of existing drugs, and investigated 
its therapeutic effects against GBM with the purpose of drug repositioning. To develop 
novel therapeutics targeting GSCs, we initially screened drug libraries for small-
molecule compounds showing a greater efficacy, compared to that of controls, in 
inhibiting the proliferation and survival of different GSC lines using cell proliferation 
assay. Drugs already reported to show therapeutic effects against GBM or those 
under clinical trials were excluded from subsequent screening. Finally, we found three 
drugs showing remarkable antiproliferative effects on GSCs at low concentrations and 
investigated their therapeutic effects on GSCs, glioma cell lines, and in a GBM mouse 
model. Of the three compounds, fluspirilene demonstrated a significant inhibitory 
effect on the proliferation and invasion of glioma cells as well as in the model mice 
treated with the drug. These effects were associated with the inactivation of the signal 
transducer and activator of transcription 3 (STAT3). Redeveloping of fluspirilene is a 
promising approach for the treatment of GBM.
INTRODUCTION
Glioblastoma (GBM) is one of the most malignant 
primary brain tumors in adults. Despite major advances 
in the diagnosis and treatment of cancer in recent 
years, GBM is still rarely curable, and most patients 
diagnosed with GBM die within 2 years. Each GBM 
tumor is composed of heterogeneous cell populations, 
including those with stem cell properties, termed glioma-
initiating cells or glioma stem cells (GSCs) [1]. GSCs are 
characterized by a highly invasive nature and resistance 
to chemo- and radiotherapy [2]. Accumulating evidence 
suggests that targeting GSCs provides considerable 
benefits in experimental settings [3, 4]. However, none 
of the agents inhibiting the signaling pathway of GSCs 
has been approved for use in the clinic.
Development of new drugs is a costly and laborious 
process with a high rate of failure. Drug repositioning 
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or drug repurposing refers to the identification of new 
indications for already approved drugs, offering promising 
options to overcome the problems of drug development [5]. 
In the past, several drugs were repurposed, including the 
anti-inflammatory agent aspirin for secondary prophylaxis 
of cerebrovascular ischemic stroke and cardiovascular 
disease [6, 7], a chemotherapeutic agent against breast 
cancer, raloxifene, for the prophylaxis of osteoporotic 
fractures [8], the sleep-inducing agent thalidomide for 
chemotherapy against multiple myeloma [9], the angina 
pectoris medication sildenafil for erectile dysfunction [10], 
and azidothymidine, which failed as a chemotherapeutic 
agent, for anti-human immunodeficiency virus (HIV) 
therapy [11].
In the present study, we identified fluspirilene, a 
traditional antipsychotic drug, as a novel therapeutic 
agent against GBM. We selected fluspirilene from 
1,301 existing compounds and examined its therapeutic 
effects both in vitro and in vivo for the purpose of drug 
repositioning. Additionally, the antitumor effect of this 
drug was revealed to attenuate the signal transducer and 
activator of transcription (STAT) 3 activity. STAT3 is 
an important transcription factor for many cytokines 
and growth factor receptors, and it is associated with 
the maintenance of cancer stem cells [12–17]. Strong 
activation of STAT3 by epidermal growth factor 
(EGF), platelet-derived growth factor, transforming 
growth factor beta (TGFβ), and interleukin-6 (IL-
6) serves as a crucial signal for the maintenance of 
GSCs and treatment resistance in GBM [12, 14]. 
STAT3 is involved in a radiation-induced proneural-to-
mesenchymal transition [13]. Consequently, targeting 
STAT3-related signaling pathways is expected to be 
a promising therapeutic approach to overcoming this 
refractory disease. Some clinical trials to develop 
STAT3-targeting drugs against malignant tumors other 
than glioma were conducted [18–20].
RESULTS
Potential candidate compounds against GBM
Of the 1,301 compounds screened, 89 compounds 
showed various degrees of viability inhibition of GSCs, 
as determined by the WST-8 cell proliferation assay 
during initial screening (Figure 1). After we excluded 
Figure 1: Schematic representation of the drug screening procedure. A total of 1,301 compounds from five libraries were 
screened by a three-step procedure. First, compounds (1, 5, 20 μM) exhibiting 25% or more reduction in the cell viability, measured by the 
WST-8 assay, were selected. Second, drugs with an already reported therapeutic potential against GBM or those under clinical trials were 
excluded. Third, drugs attenuating the cell viability and sphere-forming capacity at lower concentrations (0.2, 0.5, 1 μM) were selected. 
Some examples showing efficacy or inefficacy of 1st screening were presented in the right panels.
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the drugs that are under clinical trials for GBM or have 
already been reported to show effects on GBM cells, 
36 compounds were identified during a second round 
of screening. Among those, three drugs were selected, 
which exhibited strong inhibitory effects on the GBM 
cell viability at lower concentrations (Figure 1). Of the 
3 compounds, fluspirilene (8-[4,4-bis(4-fluorophenyl)
butyl]-1-phenyl-1,3,8-triazaspiro [4, 5] decan-4-one) 
was selected because of its novelty and efficacy in the 
treatment of GBM cells (Figure 1) and the ability to 
penetrate blood–brain barrier (BBB) [21]. Fluspirilene is 
a potent diphenylbutylpiperidine antipsychotic drug that 
has been used for the treatment of schizophrenia for many 
years. The other two compounds are being investigated as 
next candidates.
Attenuation of stemness and proliferation of 
GSCs by fluspirilene
The WST-8 assay showed that fluspirilene decreased 
the viability of all three GSC lines in a dose-dependent 
manner (Figure 2A). At concentrations of 2.5 and 5 μM, 
fluspirilene exhibited 48.7% and 43.7% reduction in 
KGS01 (p < 0.01), 20.5% and 18.1% reduction in TGS01 
(p < 0.01), and 59.2% and 40.8% reduction in TGS04 (p 
< 0.01) cell viability, respectively, but not significantly at 
the lowest concentration of 1.25 μM.
Fluspirilene also decreased the sphere formation 
by all three GSC lines in a dose- dependent manner 
(Figure 2B, 2C). The sphere numbers were reduced in 
KGS01 and TGS04 cultures at all tested concentrations 
of fluspirilene, while those in the TGS01 culture were 
reduced at fluspirilene concentrations of 5 μM and more. 
Additionally, fluspirilene at concentrations above 1.25 
μM significantly reduced the sphere sizes for KGS01 
and TGS04, while those for TGS01 were reduced at 
concentrations above 2.5 μM of fluspirilene. Notably, 
the sphere formation was completely blocked by 10 μM 
fluspirilene in all three cell lines (Figure 2C). The reduced 
stem cell properties were associated with suppression of 
SRY (sex determining region Y)-box (SOX) 2 expression 
by fluspirilene (Figure 2D). These data indicate that 
fluspirilene is effective in controlling the stem cell 
phenotype.
Effect of fluspirilene on proliferation and 
invasion of GBM cells and GSCs
When treating malignant glioma, it is reasonable 
to expect that the drug will inhibit not only GSCs but 
also differentiated tumor cells. Thus, we evaluated the 
efficacy of fluspirilene against both glioma cell lines 
and GSC lines. Fluspirilene demonstrated the inhibition 
of proliferation of T98, U87 and all GSC lines at 1.25, 
2.5, and 5 μM, while it inhibited the proliferation of U251 
and SNB19 at 2.5 and 5 μM, as determined by the Alamar 
blue assay (Figure 3A). The Transwell assay showed that 
fluspirilene inhibited the invasion of GBM cells and GSCs 
to extracellular matrix in a dose-dependent manner (Figure 
3B). The numbers of invaded GBM cells were reduced 
by 55.4% and 14.8% in SNB19 (p < 0.01), 37.1% and 
23.2% in U87 (p < 0.01), 58.0% and 23.9% in U251 (p 
< 0.01), and 66.5% and 45.2% in T98 (p < 0.01) by 1.5 
and 3 μM fluspirilene, respectively (Figure 3B). The 
numbers of invaded GSCs were reduced by 59% and 38% 
in TGS01 (p < 0.01), 70.5% and 39.6% in TGS04 (p < 
0.01), 52.7% and 35% in KGS01 (p < 0.01) by 1.5 and 3 
μM fluspirilene, respectively (Figure 3B). Taken together, 
fluspirilene can be considered a potential therapeutic agent 
against GBM composed of GSCs and differentiated tumor 
cells.
Inhibitory effect of fluspirilene on STAT3
We analyzed various signal transduction pathways 
characteristic of GBM or other malignant tumors, such as 
phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), 
Janus kinase (JAK)/STAT, cyclin-dependent kinase 2 
(CDK2), mouse double minute 2 homolog (MDM2), and 
RAF kinase/mitogen-activated protein kinase (MAPK) 
kinase (MEK)/extracellular signal-regulated kinase (ERK) 
pathways. Consequently, we identified fluspirilene to 
be a STAT3 inhibitor by monitoring the level of STAT3 
phosphorylated at the serine 727 residue [p-STAT3 
(S727)], the active form of STAT3. Western blot analysis 
showed that fluspirilene attenuated the expression level 
of p-STAT3 (S727) in a dose- dependent manner both in 
GSCs (Figure 4A) and glioma cell lines (Figure 4B). Other 
than STAT3, none of the protein molecules analyzed was 
significantly altered by fluspirilene (Supplementary Figure 
2). In addition, the inhibition of STAT3 phosphorylation 
coincided with reduced translocation of STAT3 proteins 
from the cytoplasm to the nucleus (Figure 4C).
In order to confirm whether anti-tumor effect of 
fluspirilene is due to only STAT3 inhibition, Alamar blue 
proliferation assay was performed using fluspirilene, 
STAT3 siRNA, and their combination. Reduction of 
STAT3 protein expression by siRNA was illustrated in 
all tested GBM cells compared with untransfected and 
negative control (NC) siRNA-transfected cells (Figure 
5A). Fluspirilene showed little additive effect on the cell 
viability in combination with STAT3 siRNA treatment 
(Figure 5B).
Based on the results of the in vitro study and 
following an institutional review board- approved 
protocol, we conducted an in vivo tumor-forming assay. 
The tumor histology of our animal model demonstrated 
several features characteristic of host GBM, including a 
highly proliferative and invasive nature (Supplementary 
Figure 1B). The number of diffusely infiltrating satellite 
lesions that were stained positive for nestin significantly 
decreased in the fluspirilene-treated mice (Figure 6A). 
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Figure 2: Fluspirilene inhibited viability and suppressed sphere-forming ability of three stem cell lines in a dose-
dependent manner by down-regulating SOX2. (A) Viability of GSCs was assessed by the WST-8 assay 48 h after the treatment 
with fluspirilene at various concentrations. **p < 0.01. (B) Micrographs show representative tumorspheres formed by relatively sensitive 
KGS01, TGS01, and TGS04 cells after 7 days of fluspirilene treatment. Scale bar = 200 μm. (C) The sphere numbers and sizes dramatically 
decreased in sensitive lines with 1.25 μM or 2.5 μM fluspirilene treatment. The sphere numbers strongly decreased in GSCs at fluspirilene 
concentrations of more than 2.5 μM. Sphere formation by all three GSC lines was diminished with 10 μM fluspirilene. The sphere sizes of 
GSCs were significantly reduced in a dose-dependent manner. *p < 0.05, **p < 0.01. (D) Fluspirilene attenuated the expression of SOX2 in 
dose dependent manner. β-actin was used as a loading control.
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Figure 3: Effects of fluspirilene on proliferation and invasion of GBM cells. (A) Cells were treated with fluspirilene at 1.25, 
2.5, and 5 μM, and viability curves of GBM cell lines were analyzed in the presence and absence of fluspirilene. The plate was read 
on a plate reader at the indicated time points. (B and C) Cells were treated with fluspirilene at 1.5 and 3 μM. Cells invading through a 
Matrigel-coated Transwell chamber were scored in the presence and absence of fluspirilene for 8 h. The mean numbers of cells and standard 
deviations were calculated for eight high-power microscopic fields. *p < 0.05, **p < 0.01.
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Notably, well-demarcated borders were observed between 
the tumor and adjacent normal brain tissues (Figure 6A). 
Moreover, the mice treated with fluspirilene showed 
a remarkable reduction of the tumor size compared 
with that in the control group (Figure 6B). Notably, 
fluspirilene significantly prolonged survival of the mouse 
model (Figure 6C). Inhibition of the STAT3 activity by 
fluspirilene was also confirmed by a decreased level of 
p-STAT3 (S727) in mouse brain tumor (Figure 7). These in 
vivo data were consistent with the in vitro results.
DISCUSSION
In the present study, we demonstrated that 
fluspirilene, selected from five drug libraries composed 
of 1,301 compounds, suppressed the proliferation and 
invasion of patient-derived GSCs, glioma cells, and 
mouse brain tumor via inactivation of STAT3, suggesting 
that fluspirilene has a novel therapeutic potential against 
GBM as a repositioned drug. Fluspirilene, one of classic 
antipsychotic drugs, inhibits dopamine D2 receptor and 
sedates the positive symptoms of schizophrenia. This drug 
is administered by intramuscular injection as a suspension 
in water and acts sustainedly.
It has been well established that effective elimination 
of cancer stem cells is a key in the treatment of malignant 
tumors, including GBM. Previously, Gupta and colleagues 
[22] have established a drug screening system to select 
specific inhibitors of breast cancer stem cells using a 
chemical library including about 16,000 compounds. In 
this study, we identified fluspirilene as an agent inhibiting 
viability of GSCs and differentiated GBM cells, which 
demonstrated that our drug screening system was practical 
for the isolation of small-molecule compounds for the 
treatment of GBM. Tsukamoto et al. designed a screening 
system for a unique compound library, containing 
nucleosides, sugars, peptides, kinase inhibitors, and 
natural products, using a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay [23]. We 
adopted a screening system using existing drug libraries. 
Hegazy et al found several drugs that suppressed the 
mitochondrial activity of GSCs using this system [24].
Repositioning of existing drugs has drawn attention 
as a promising drug discovery approach for GSC-targeted 
Figure 4: Inhibition of STAT3 activity and modulation of STAT3 translocation into the nucleus by fluspirilene. (A) 
Changes in the levels of STAT3 phosphorylated at serine 727 residue [p-STAT3 (S727)] and total STAT3 were analyzed by 
western blotting in GSCs and GBM cells following the treatment with fluspirilene for 48 h. β-actin was used as a loading 
control. The bar graphs below the blots show relative levels of p-STAT3 (S727) quantified by densitometry and normalized 
to those of total STAT3. (B) Nuclear content of STAT3 reduced in GBM cell after 1.5 µM of fluspirilene treatment. STAT3 
(red), DAPI (blue). Scale bar 100μm.
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therapy. Among potential drug candidates for repurposing 
antipsychotics, mood stabilizers, anticonvulsants, and 
small molecules that can easily pass through BBB may be 
useful for treating GBM [25]. A number of antipsychotic 
drugs, mood stabilizers, and antiepileptic drugs have 
shown antitumor effects [26]. These drugs with the 
inherent ability to penetrate BBB have shown the anti-
GBM potential through different mechanisms, such as 
the inhibition of actin polymerization by fluvoxamine 
[27], stimulation of AMP-activated protein kinase by 
olanzapine [28, 29], inhibition of histone deacetylases by 
valproate [30–34], and inhibition of glycogen synthase 
kinase 3 beta (GSK3β) by lithium [35–40]. Several small-
molecule compounds have shown an anti-glioma potential. 
Thus, nitroxoline, an FDA-approved antibiotic, induced 
the apoptosis via caspase-3 [41], and disulfiram, used 
for the treatment of substance abuse, has shown various 
inhibitory effects on cancer stem cell signals [42]. Many 
drugs face economic barriers, such as being off-patent, 
which may discourage pharmaceutical companies from 
getting involved. Moreover, not all drugs succeed in the 
redevelopment, although phase I trials can be omitted. 
Thus, systematic screening using drug libraries, as in this 
study, is necessary.
STAT3 has been characterized as one of the major 
drivers of GBM, contributing to the maintenance of 
stemness and a mesenchymal phenotype via the IL-6/
glycoprotein 130 (GP130)/STAT3 or EGF receptor 
(EGFR)/JAK2/STAT3 axis and leading to chemo- and 
radiation resistance of the tumor [43–45]. It has been 
shown that inhibition of STAT3 activation decreased the 
cell proliferation and invasion and enhanced the sensitivity 
to chemotherapy [13, 46]. In this study, fluspirilene was 
found to inhibit STAT3 activation, affecting not only 
GSCs but also GBM cells. However, it was not elucidated 
whether fluspirilene inhibits the STAT3 activity directly 
or indirectly, by acting on its upstream signals. Leigens 
and colleagues [47] have confirmed that metformin 
directly inhibited the STAT3 phosphorylation in vitro, 
using GSCs with altered STAT3 expression. Inhibition 
of IL-6 has been found to decrease the level of STAT3 
phosphorylation, followed by downregulation of cyclin 
D1 [48]. Transcriptional activity of STAT3 is regulated by 
phosphorylation of the S727 residue via MAPK signaling or 
the PI3K/AKT/mechanistic target of rapamycin (mTOR) 
axis [49]. Involvement of the MEK/ERK/STAT3 pathway 
has been reported to suppress the ultraviolet B-induced 
apoptosis in melanoma [50]. In our study, declines in the 
Figure 5: Fluspirilene as a potential STAT3 inhibitor. (A) Extracts of U251, SNB19, T98, and U87 cells treated by siRNA for 
STAT3 or negative control (NC) were immunoblotted with antibodies against STAT3 or β-actin. (B) The viability of the GBM cells treated 
with fluspirilene (F) and STAT3 siRNA was significantly reduced, whereas little difference was found between STAT3 siRNA and the 
combination of STAT3 siRNA and fluspirilene on the cell viability.
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Figure 6: Effect of fluspirilene treatment on the GBM animal model. (A) Representative histologic and immunohistochemical 
sections of untreated and fluspirilene-treated brain tumors. Tumor cells were detected by staining for nestin. A magnified image of the inset 
is shown below the nestin panel. Mice treated with fluspirilene showed a well-demarcated border between the tumor and adjacent normal 
brain tissue. Scale bar = 100 μm. (B) Mice treated with fluspirilene showed a remarkable reduction of the tumor size compared with that 
in the control group. *p = 0.017. (C) Survival of mice treated with fluspirilene and DMSO (control). Fluspirilene significantly prolonged 
survival of the TGS04 mouse model. Log-rank test, p = 0.026.
Figure 7: Inhibition of STAT3 activity by fluspirilene in mouse brain tumor. Representative immunohistochemical sections of 
untreated and fluspirilene-treated brain tumors. Activity of STAT3 [level of p-STAT3 (S727) in nuclei] decreased in the mice treated with 
fluspirilene compared with that in the control group. *p < 0.05. Scale bar = 100 μm.
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levels of phosphorylated proto-oncogene tyrosine-protein 
kinase MDM2, CDK2, Akt, ERK, SRC, c-Jun N-terminal 
kinase (JNK), and p38 kinase were observed in some 
cell lines (Supplementary Figure 2), suggesting that the 
efficacy of fluspirilene varied among individual cases with 
different molecular profiles. SRC is activated by EGFR 
and induces the gene expression of factors necessary 
for the maintenance of GSCs, such as SOX1, C–X–C 
chemokine receptor type 4 (CXCR4), distal-less (DLL) 
protein, and neurogenic locus notch homolog protein 3 
(NOTCH3), through the phosphorylation of STAT3 [51]. 
Fluspirilene treatment exhibited anti-tumor activity for 
hepatocellular carcinoma by inhibiting CDK2 [52] and 
induction of autophagy [53]. However, fluspirilene did not 
enhance the siSTAT3 treatment on cell viability (Figure 
5). Taken together, it is speculated that STAT3 inhibitory 
potential of fluspirilene can be a major mechanism of anti-
tumor effect in GBM.
A small number of drugs targeting STAT3 are 
under development. Three phase 1 studies reported 
limited antitumor effect due to common but dose-
limiting adverse events such as gastrointestinal disorder, 
myelosuppression, peripheral neuropathy, and fatigue 
[18, 54, 55]. Peripheral neuropathy might not reflect 
cumulative toxicity because of its early onset compared 
with other forms of chemotherapy-induced neuropathy. 
Nerve growth factor- induced neurite outgrowth occurs 
via STAT3 activation in mitochondria not in nuclei [56], 
suggesting on-target effect of STAT3 inhibitors. Currently, 
ruxolitinib, a JAK1/2-targeting agent, is widely used for 
myelofibrosis and polycythemia vera [57, 58] and showed 
suppression of phosphorylated STAT3 in dose dependent 
manner [59]. Since there are many problems to be solved 
in the development of STAT3 inhibitory treatment, 
repurposing of the existing drug fluspirilene is promising 
as a STAT3-targeted therapy that can be introduce in clinic 
immediately.
JNK and p38 are downstream signaling molecules 
of TGFβ and mixed-lineage kinase (MLK) whose 
expression is enhanced in the mesenchymal subtype [14, 
60, 61]. It was suggested that MAPK signaling related 
to TGFβ was involved in the STAT3 suppression by 
fluspirilene. On the other hand, fluspirilene might act 
specifically on STAT3 since it caused little changes in 
the molecular expression other than that of STAT3. Thus, 
we plan to focus on TGFβ and related MAPK systems 
as well as on the alteration of signaling necessary for the 
maintenance of stemness.
In conclusion, fluspirilene is a promising medicine, 
which not only suppresses GSCs but also shows effects 
on differentiated GBM cells. GBM is thought to be 
a mixture of GSC, its differentiated cells, reactive 
astrocyte, tumor-associated microglia/macrophage 
(TAM), etc. Thus, new drug or strategy for GBM 
treatment expected to have multi-acting potential against 
these components. There are, however, many aspects 
to be further clarified, such as detailed signal analysis 
of antitumor effects related to STAT3. In the future, to 
ascertain the effects of fluspirilene for drug repurposing, 
additional preclinical studies are required to confirm 
that fluspirilene contributes beneficially to the GBM 
treatment. Finally, clinical studies are needed to validate 
the efficacy and safety of fluspirilene, in combination 




Human GBM cell lines, U251, SNB19, T98, 
and U87 were purchased from American Type Culture 
Collection (Manassas, WA, USA) in 2009. These cell 
lines were characterized at the Resource Institute by short 
tandem repeat profile analysis. Authentication of the cell 
lines was unnecessary because they were expanded by 
culturing them for fewer than two passages and stored 
at −80°C. Low-passage cells were used for experiments 
within a period of 6 months after resuscitation. Cells were 
cultured at 37°C in a 5% CO2 incubator and maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS).
Among human patient-derived GBM cell lines, 
TGS01 and TGS04 were established at University of 
Tokyo [62], and KGS01 was established at Kanazawa 
University. The use of these human materials and the 
protocols were approved by the Ethics Committees of 
Kanazawa University and University of Tokyo. TGS01 
and TGS04 have already been confirmed as tumor-
initiating cells since cultured cells have the self-renewal 
ability in vitro and recapitulate the original tumor in a 
mouse xenograft model [62]. KGS01 was also confirmed 
as a GSC line. Briefly, KGS01 had the ability to form 
spheres and express surface markers characteristic of 
stemness, such as CD133 [1], CD44 [63], and nestin 
[64, 65] (Supplementary Figure 1A). KGS01 could 
differentiate into glial fibrillary acidic protein (GFAP)- 
and oligodendrocyte transcription factor (Olig2)-positive 
astrocyte-like cells as well as into neuron-specific class 
III beta-tubulin (Tuj1)-positive neuron-like cells in 
DMEM supplemented with 10% FBS (Supplementary 
Figure 1A) and grow into brain tumor, histologically 
recapitulating features of the original in vivo GBM 
(Supplementary Figure 1B). These cells were cultured in 
neurosphere medium containing DMEM/F12 (Gibco, Life 
Technologies, Carlsbad, CA, USA) supplemented with 
recombinant human EGF at 20 ng/mL (Sigma–Aldrich, 
St. Louis, MO, USA), recombinant human basic fibroblast 
growth factor at 20 ng/mL (Sigma–Aldrich), B27 




We used the following five SCREEN-WELL® 
libraries from Enzo Life Sciences (Farmingdale, NY, USA): 
1) FDA (U.S. Food and Drug Administration)-approved 
drug library (640 compounds; CB-BML-2841J0100); 2) 
ICCB (Harvard Institute of Chemistry and Cell Biology) 
known bioactives library (480 compounds; CB-BML-
2840J0100); 3) kinase inhibitor library (80 compounds; 
CB-BML-2832J0100); 4) fatty acid library (68 compounds; 
CB-BML-2803J0100); and 5) phosphatase inhibitor library 
(33 compounds; CB-BML-2834J0100). To identify effective 
compounds among the 1,301 compounds, three-step 
screening was performed (Figure 1). First, the three GSC 
lines (TGS01, TGS04, and KGS01) were treated with each 
compound provided in the libraries at three concentrations (1, 
5, and 20 μM) in a 384-well plate (Corning, Cambridge, MA, 
USA) for 48 h, followed by a 2-(2-methoxy-4-nitrophenyl)-
3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 
(WST-8) cell viability assay as described below. Compounds 
exhibiting 25% or more reduction in cell viability in a dose-
dependent manner were selected. Second, drugs that have 
already been reported to have a therapeutic potential against 
GBM or those in clinical trials were excluded. Third, the 
WST-8 assay and sphere-forming assay were performed 
using the three GSC lines with lower concentrations (0.2, 
0.5, and 1 μM) of the selected compounds. Candidate drugs 
were identified as demonstrating remarkable inhibition of 
cell viability even at the lowest concentration.
Cell viability assay
GSC viability was assessed using a Cell Counting 
Kit-8 (Dojindo, Kumamoto, Japan) following the 
manufacturer’s instructions. Briefly, GSC spheres were 
dissociated into single cells with StemPro Accutase 
(Gibco). Then, the cells were seeded into a 96-well Costar 
ultra-low attachment plate (Corning) at a density of 1 × 
103 cells/100 μL. The relative numbers of viable cells 
were determined by measuring the absorbance with the 
WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium) assay kit using a 
microplate reader.
An Alamar blue assay (Biosource, Camarillo, CA, 
USA) was performed to examine the viability of the GBM 
cell lines. According to the manufacturer’s manual, 1 × 
103 GBM cells of each type were seeded into wells of a 
96-well plate in 200 μL of culture medium supplemented 
with 0.1% FBS. After 4 h of incubation at 37°C, 20 μL 
of Alamar blue was added to each well. The plate was 
read on a fluorescence plate reader at 0, 24, 48, 72, and 
96 h. The average fluorescence values from eight wells 
were calculated and plotted. To investigate the effect of 
fluspirilene on cell proliferation, cells were treated with 
various concentrations of fluspirilene.
Tumor sphere-forming assay
The sphere-forming assay was performed as 
described previously [66, 67]. Briefly, GSC spheres 
were dissociated into single cells with StemPro Accutase 
(Gibco). Then, 1 × 103 single cells were seeded in a 96-
well Costar ultra-low attachment plate (Corning) in 200 
μL of neurosphere medium supplemented with 1.0% 
methylcellulose. The cells were treated with either 
fluspirilene (Sigma–Aldrich) or dimethyl sulfoxide 
(DMSO). The numbers of tumor spheres were counted, 
and the tumor sphere diameters were measured after 7 
days of incubation.
Matrigel invasion assay
Cell invasion assays were performed using 
modified Boyden chambers consisting of Transwells 
with Matrigel-pre-coated membrane filter inserts in 24-
well tissue culture plates (BD Biosciences, San Jose, CA, 
USA), as described previously [68]. Serum-deprived 
GBM cells were suspended in DMEM supplemented 
with 0.1% FBS and added to each Transwell. GSC 
spheres were dissociated into single cells with StemPro 
Accutase (Gibco). GSCs were suspended in F12/DMEM 
supplemented without growth factor and added to each 
Transwell. After 16–20 h of incubation at 37°C, the non-
invasive cells were removed by wiping the upper side of 
the filter, and the invasive cells were fixed with methanol 
and stained using a Diff-Quik kit (Sysmex, Kobe, Japan). 
The invaded cells were counted on the filter in six 
microscopic fields randomly selected at a high power, 
and the mean number of invasive cells was calculated 
and analyzed. 
Western blot analysis
Cellular proteins were extracted from cultured 
cells following the treatment with lysis buffer (Sigma–
Aldrich) containing a mixture of protease and phosphatase 
inhibitors (Sigma–Aldrich). A 15-μg aliquot of the whole 
protein extract was analyzed by a western immunoblot 
assay for the protein of interest (Supplementary Table 1), 
as previously described [68].
Silencing of endogenous STAT3 with small 
interfering RNA
Purified duplexed small interfering RNA (siRNA) 
for STAT3 and control luciferase were purchased from 
QIAGEN. Ten nanomolar siRNA was transfected into 
cells cultured in 6-well plate using Avalanche®-Omni 
Transfection Reagent (APRO SCIENCE, Tokushima, 
Japan). Transfected cells were cultured for 48 h before 
use.
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Mouse model of GBM and treatment
Following an institutional review board-approved 
protocol, we generated a mouse brain tumor model of 
human GBM by transplantation of TGS04 cells into the 
brain of nude mice (BALB/cSlc-nu/nu, Charles River 
Laboratories, Osaka, Japan) according to our previous 
study [69]. Briefly, a burr hole was made in the skull 3 
mm lateral to the bregma using a drill, and 3 × 104 TGS04 
cells were stereotactically injected at a depth of 3 mm 
below the dura mater. The mice were randomly assigned 
to two groups and treated with either fluspirilene (n = 5) 
or with DMSO as a control group (n = 5). All mice were 
given intramuscular injections of 200 μL of DMSO or 
fluspirilene dissolved in DMSO at 1 mg/kg body weight 
four times. The dose of fluspirilene corresponded to the 
concentration of the drug in culture medium used in the 
treatment of cells in vitro. Assuming that 60% of body 
weight is accounted for by body fluid in each mouse, the 
dose of fluspirilene of 1mg/kg corresponded approximately 
to concentration of 5 μM in culture medium. After 6 weeks 
of treatment, all ten mice were euthanized.
The brain tissues were dissected, embedded in 
paraffin, and then cut into 4-μm serial coronal sections. 
The tissue sections were stained using a standard 
hematoxylin and eosin staining technique. We calculated 
the surface included by the tumor contour of the region 
of interest in coronal section showing the maximal area 
of each tumor. For estimates of overall survival time, the 
mice were randomly assigned to two groups for treatment 
with fluspirilene (n = 10) and with DMSO as a control 
group (n = 10). All animal experiments followed the 
Guidelines for the Care and Use of Laboratory Animals 
at Kanazawa University that covers the national guideline.
Immunohistochemistry and immunofluorescence 
assay
For immunohistochemistry, 4-μm thick paraffin-
embedded tissue blocks were sectioned onto slides and 
deparaffinized. The sections were microwaved for 15 min 
in citrate buffer (pH 6.0), quenched with 0.3% hydrogen 
peroxide (H2O2) in methanol for 20 min, and blocked for 
20 min with skim milk. The slides were incubated with 
each primary antibody (Supplementary Table 1) or with 
nonimmune mouse or rabbit IgG as a negative control 
overnight at 4°C, then washed, and immunostained 
using an Envision+ kit (Dako, Tokyo, Japan) for 60 min 
at room temperature. The color was developed using 
3,3′-diaminobenzidine tetrahydrochloride for 5 min, and 
the sections were then counterstained with hematoxylin.
For immunofluorescence assay, cells were fixed 
with 4% paraformaldehyde and then permeabilized. After 
washing with phosphate-buffered saline, the cells were 
blocked with 5% skim milk for 30 min and incubated with 
each antibody (Supplementary Table 1) for 1 h at 25°C, 
followed by incubation with an Alexa Fluor 488 goat anti-
rabbit antibody or an Alexa Fluor 546 anti-mouse antibody 
for 1 h at room temperature in the dark. Finally, the 
sections were washed with Tris-buffered saline containing 
Tween 20 and mounted with mounting medium for the 
fluorescence assay with 4′,6-diamidino-2-phenylindole 
(Santa Cruz Biotechnology, CA, USA). Images were 
acquired using a BZ-X700 microscope (Keyence, Osaka, 
Japan) and digitally processed with the Keyence analysis 
software (Keyence).
Statistical analysis
The data are presented as the mean ± standard 
deviation. Statistically significant differences in the 
mean or median values between the two groups were 
tested by the Student’s t-test or Mann–Whitney U-test 
as appropriate. Log-rank analysis was used to determine 
statistical significance of Kaplan-Meier survival curve. A 
value of p < 0.05 was considered to indicate a statistically 
significant difference. All statistical calculations were 
performed using the SPSS software, version 19.0 (SPSS, 
Inc., Chicago, IL, USA).
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